Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1385&sort=-other_investigators
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-other_investigators", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1419&sort=-other_investigators", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1386&sort=-other_investigators", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1384&sort=-other_investigators" }, "data": [ { "type": "Grant", "id": "10409", "attributes": { "award_id": "1F32HL162428-01", "title": "The Role of Macrophages in Pulmonary Regeneration using a Bioengineered Whole Lung Tissue Model", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 23761, "first_name": "JINING", "last_name": "Lu", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-07-01", "end_date": "2025-06-30", "award_amount": 67174, "principal_investigator": { "id": 26406, "first_name": "Allison Marie", "last_name": "Greaney", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 210, "ror": "https://ror.org/042nb2s44", "name": "Massachusetts Institute of Technology", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "Fibrotic lung remodeling is a hallmark of many lung diseases, including severe influenza infection, idiopathic pulmonary fibrosis, and COVID-19. While a basal-like epithelial cell has been identified as a central player to this aberrant repair response, little has been done to investigate the behavior and interactions of other cells in the diseased tissue, particularly alveolar macrophages. Therefore, the goal of this study is to leverage a biomimetic engineered lung model system to investigate the relationship between regenerating basal-like progenitor cells and pulmonary macrophages. This engineered lung tissue system is based on cellular repopulation and culture of a decellularized native rat lung scaffold. This platform enables a well-controlled, native-like tissue environment for the evaluation of cell-cell interactions, without the systemic confounders of in vivo studies. It is expected that macrophages will significantly influence and direct epithelial remodeling by these basal-like cells, particularly in relation to the fibrotic or anti-fibrotic activation state of the macrophages. This work expands on previous findings that adding macrophages to engineered lung cultures containing basal-like progenitor cells significantly improves tissue architecture and regenerative epithelial cell phenotype, compared to engineered lung cultures without macrophages. First, pulmonary macrophages will be isolated from rats by bronchoavleolar lavage and characterized. Protocols will be developed to chemically stimulate macrophages in vitro to a disease-like inflammatory state, or to a reparative anti-fibrotic state. Next, macrophages of different activation states will be introduced to air-liquid interface cultures of regenerative basal cells, to evaluate epithelial-macrophage interactions in isolation. Finally, activated macrophages will be introduced to engineered lung cultures containing regenerative basal cells, fibroblasts, and endothelium to recapitulate essential native cellular communities. Engineered lung tissues will be evaluated for histologic and biomechanic changes between conditions, as well as differential cell signaling patterns, as evaluated by single-cell RNA sequencing. It is expected that inflammatory macrophages will contribute to fibrotic response in regenerating epithelium, whereas anti-fibrotic macrophages will contribute to more functional alveolar regeneration by basal-like cells. The findings of this study will elucidate the role of pulmonary macrophages in governing lung repair and regeneration in this model system. Further, this work may suggest possible routes for the treatment of fibrotic lung diseases. The proposed research project will be executed by Allison M. Greaney at the David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (MIT), under the Sponsorship of Dr. Robert Langer, and Co-Sponsorship of Dr. Ruslan Medzhitov at Yale University. Dr. Langer and Dr. Medzhitov will mentor Allison in her Research and Professional Training Goals to develop new research and scientific communication skills, so she may be well-equipped to secure a tenure-track faculty position at a top research institution.", "keywords": [ "Air", "Alveolar", "Alveolar Cell", "Alveolar Macrophages", "Anti-Inflammatory Agents", "Apoptotic", "Architecture", "Basal Cell", "Behavior", "Benchmarking", "Biological Models", "Biomechanics", "Biomedical Engineering", "Biomimetics", "Bronchoalveolar Lavage", "COVID-19", "Cell Communication", "Cells", "Cessation of life", "Chemicals", "Coculture Techniques", "Communication", "Data", "Dinoprostone", "Disease", "Disease Outcome", "Distal", "Endothelium", "Engineering", "Environment", "Epithelial", "Epithelial Cells", "Evaluation", "Faculty", "Fibroblasts", "Fibrosis", "Goals", "Histologic", "Homeostasis", "Human", "Hypoxemia", "In Vitro", "Inflammatory", "Injury", "Institutes", "Institution", "Interferon Type II", "Interferons", "Interleukin-4", "Intervention", "Irrigation", "Lead", "Lipopolysaccharides", "Liquid substance", "Lung", "Lung diseases", "Maintenance", "Massachusetts", "Mentors", "Mesenchymal", "Mesenchyme", "Methods", "Muscle", "Myoblasts", "Myofibroblast", "Natural regeneration", "Paracrine Communication", "Pattern", "Pharmacology", "Phenotype", "Play", "Population", "Positioning Attribute", "Production", "Proteins", "Protocols documentation", "Publishing", "Rattus", "Reporting", "Research", "Research Project Grants", "Role", "Route", "SARS-CoV-2 infection", "Secure", "Signal Transduction", "Site", "Skeletal muscle injury", "Structure of parenchyma of lung", "System", "Technology", "Therapeutic Intervention", "Tissue Model", "Tissues", "Training", "Universities", "Vascular Endothelium", "Work", "alveolar epithelium", "anticancer research", "base", "cell community", "cell stroma", "cell type", "cytokine", "epithelial repair", "epithelial stem cell", "epithelium regeneration", "fibrotic lung", "fibrotic lung disease", "idiopathic pulmonary fibrosis", "improved", "in vivo", "influenza infection", "insight", "lung regeneration", "lung repair", "macrophage", "novel", "organ growth", "progenitor", "recruit", "regenerative", "repaired", "response", "restoration", "scaffold", "severe injury", "single-cell RNA sequencing", "skills", "stem cells", "tenure track" ], "approved": true } }, { "type": "Grant", "id": "10410", "attributes": { "award_id": "1S10OD032325-01", "title": "Cytek Aurora Full Spectrum Flow Cytometer", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 11602, "first_name": "GUANGHU", "last_name": "Wang", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-20", "end_date": "2023-09-19", "award_amount": 468316, "principal_investigator": { "id": 26407, "first_name": "Yoav", "last_name": "Altman", "orcid": null, "emails": "[email protected]", "private_emails": null, "keywords": "[]", "approved": true, "websites": "[]", "desired_collaboration": "", "comments": "", "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1428, "ror": "https://ror.org/03m1g2s55", "name": "Sanford Burnham Prebys Medical Discovery Institute", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Sanford Burnham Prebys Medical Discovery Institute (SBP) has ~40 labs studying the molecular and cellular underpinnings of diverse biological processes including cancer; developmental biology; immuno-oncology; infection, inflammation; aging and related diseases. Many recent advances in health care depend upon new insights into tissue heterogeneity at the single cell level. Flow cytometry is the gold standard for high throughput single cell analysis, however conventional flow is limited by the number of analytes that can be run in unison. Spectral flow cytometers recently achieved the parameter depth required for deep immune profiling with publications showing 40+ color rivaling time-of-flight mass cytometry (CyTOF) parameter depth with ~50-fold higher throughput. SBP requests support for a Cytek Aurora Spectral Flow Cytometer with 5 lasers (UV/V/B/YG/R), 64 fluorescence and 3 scattering channels, and Automatic Micro-sampling Station (AMS) to enable high- parameter single-cell proteomic analysis for deep profiling of cell heterogeneity in tissues. We also request support for a BioBUBBLE Class I Negative Biocontainment Enclosure for Cytek Aurora to protect researchers running potentially infectious material. The Aurora more than doubles the number of fluorescent parameters that can be measured at SBP and leverages existing FACS protocols and expertise. It is a bridging technology between high-throughput low-plex conventional flow cytometers in SBP’s Core and high-plex low- throughput genomics-based single-cell Seq technologies. This application is supported by a coalition of 12 Major Users from SBP and nearby University of California San Diego (UCSD) and San Diego Biomedical Research Institute (SDBRI) demonstrating the broad impact for the region. NIH-funded researchers, together accounting for 75% of the Aurora’s available use time (AUT), need the Aurora to advance their understanding of T cell exhaustion, anti-tumor immunity, aging, multi-system inflammatory disease in children (MIS-C), gut mucosal immunity, melanoma, pancreatic cancer, breast cancer, pediatric medulloblastoma, graft versus host disease, and the immune evasion tactics of Coronavirus. The Aurora will provide unprecedented insight into tissue signatures that correlate with health and disease leading to new mechanistic inquiries and discoveries.", "keywords": [ "Accounting", "Aging", "Biological Process", "Biomedical Research", "California", "Cells", "Child", "Childhood Medulloblastomas", "Color", "Coronavirus", "Cytometry", "Developmental Biology", "Disease", "Flow Cytometry", "Fluorescence", "Funding", "Genomics", "Gold", "Gut Mucosa", "Health", "Healthcare", "Heterogeneity", "Immune", "Immune Evasion", "Immunooncology", "Infection", "Inflammation", "Inflammatory", "Institutes", "Lasers", "Malignant Neoplasms", "Malignant neoplasm of pancreas", "Measures", "Medical", "Molecular", "Mucosal Immunity", "Proteomics", "Protocols documentation", "Publications", "Research Institute", "Research Personnel", "Running", "Sampling", "T-Lymphocyte", "Technology", "Time", "Tissues", "Tumor Immunity", "United States National Institutes of Health", "Universities", "base", "exhaustion", "graft vs host disease", "high standard", "insight", "malignant breast neoplasm", "melanoma", "single cell analysis", "time use" ], "approved": true } }, { "type": "Grant", "id": "10411", "attributes": { "award_id": "1R43HL158362-01A1", "title": "Intravenous delivery of oxygen microbubbles for the treatment of hypoxia and ARDS", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 22589, "first_name": "CHRISTIAN RENE", "last_name": "Gomez", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-20", "end_date": "2023-08-31", "award_amount": 305538, "principal_investigator": { "id": 26408, "first_name": "Benjamin", "last_name": "Arcand", "orcid": null, "emails": "[email protected]", "private_emails": null, "keywords": "[]", "approved": true, "websites": "[]", "desired_collaboration": "", "comments": "", "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1929, "ror": "", "name": "AGITATED SOLUTIONS, LLC", "address": "", "city": "", "state": "MN", "zip": "", "country": "United States", "approved": true }, "abstract": "The goal of this Phase 1 project is to develop the AS-O2-001 System for intravenous, gaseous oxygen microbubble delivery for treatment of hypoxia. Hypoxia is a catastrophic illness that can result from acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, COVID-19, congestive heart failure and myocardial infarction. Current treatment options for severely affected patients include extracorporeal membrane oxygenation (ECMO) and mechanical ventilation, which are both invasive, expensive, and have iatrogenic sequalae. Agitated Solutions Inc. is developing a novel, minimally invasive alternative: the AS-O2-001 system delivers gaseous oxygen microbubbles into the inferior vena cava to delay or prevent mechanical ventilation or ECMO. Gaseous oxygen delivery has historically resulted in emboli formation; however, improved technology today enables the delivery of microbubbles (<100 µm). Microbubbles have unique properties, including their shrinking collapse, accelerated diffusion of gases, and negatively charged surface that prevents coalescence into emboli. Supersaturated oxygen is one such therapy that utilizes microbubbles of oxygen and has seen success in acute treatments (e.g. myocardial infarctions), but cannot readily be applied for chronic illness such as hypoxia due to fluid overload. Other alternative treatments in development, such as chemically coated microbubbles or intravascular respiratory assist catheters, have seen adverse metabolic effects or cardiac intolerance that prevent their clinical adoption. The AS-O2-001 system is promising because it utilizes the safety and efficacy of microbubbles in supersaturated oxygen but removes the overburden of fluids which would be deleterious in severely ill patients with hypoxia. Furthermore, the AS-O2-001 system is applied in the inferior vena cava and takes lessons learned from intravascular respiratory assist catheters in order to prevent cardiac intolerance, including a small form factor, a small insertion size, and the use of biocompatible materials. In Aim 1, the AS-O2-001 System will be developed and tested in an in vitro model to characterize its safety in preventing formation of air emboli and its effectiveness in delivering a therapeutic relevant dose. In Aim 2, the System will be evaluated in vivo to demonstrate the safety and proof of concept of intravenous delivery of oxygen in a porcine model of normoxemia and hyperoxemia. Successful completion of this project will demonstrate the feasibility of this novel and innovative method of delivering therapeutic oxygen as intravenously injected microbubbles.", "keywords": [ "Acute", "Acute Lung Injury", "Acute Respiratory Distress Syndrome", "Acute myocardial infarction", "Adoption", "Adverse effects", "Affect", "Air", "Alveolar", "Animals", "Beak", "Behavior", "Biocompatible Materials", "Blood", "Blood Circulation", "Bypass", "COVID-19", "Cannulas", "Carbon Dioxide", "Cardiac", "Cardiopulmonary", "Cardiovascular system", "Catastrophic Illness", "Catheters", "Cell Membrane Permeability", "Charge", "Chemicals", "China", "Chronic Disease", "Chronic Obstructive Pulmonary Disease", "Clinical", "Congestive Heart Failure", "Continuous Infusion", "Continuous Positive Airway Pressure", "Critical Illness", "Dangerousness", "Development", "Devices", "Diagnostic", "Diffuse", "Diffusion", "Dose", "Dysbarism", "Effectiveness", "Embolism", "Extracorporeal Membrane Oxygenation", "FDA approved", "Family suidae", "Femoral vein", "Fluid overload", "Future", "Gases", "Goals", "Heart", "Heart failure", "Hour", "Hypercapnia", "Hypoxemia", "Hypoxemic Respiratory Failure", "Hypoxia", "Iatrogenesis", "Inferior vena cava structure", "Infusion Pumps", "Infusion procedures", "Injections", "Intravenous", "Ischemic Stroke", "Knowledge", "Liquid substance", "Lung", "Measures", "Mechanical ventilation", "Mechanics", "Metabolic", "Metals", "Methods", "Microbubbles", "Modeling", "Myocardial", "Myocardial Infarction", "Nitrogen Dioxide", "Nose", "Oxygen", "Patients", "Peripheral", "Phase", "Physiological", "Practice Management", "Pre-Clinical Model", "Procedures", "Property", "Pulmonary Fibrosis", "Ramp", "Renal function", "Safety", "Sample Size", "Scientist", "Septic Shock", "Sheep", "Surface", "System", "Systems Development", "Techniques", "Technology", "Testing", "Therapeutic", "Tissues", "Translating", "Treatment Efficacy", "Variant", "absorption", "alternative treatment", "clinical practice", "cost", "critical limb Ischemia", "effective therapy", "hemocompatibility", "hemodynamics", "high risk", "hyperbaric chamber", "improved", "improved outcome", "in vitro Model", "in vivo", "innovation", "lung injury", "minimally invasive", "normoxia", "novel", "oxygen toxicity", "porcine model", "preclinical study", "pressure", "prevent", "prototype", "respiratory assist", "risk minimization", "success", "ultrasound" ], "approved": true } }, { "type": "Grant", "id": "10412", "attributes": { "award_id": "1S10OD028674-01A1", "title": "Whole-Room Calorimeter", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 25507, "first_name": "Xiang-Ning", "last_name": "Li", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-15", "end_date": "2023-09-14", "award_amount": 1284000, "principal_investigator": { "id": 26409, "first_name": "ARLENE B", "last_name": "CHAPMAN", "orcid": null, "emails": "[email protected]", "private_emails": null, "keywords": "[]", "approved": true, "websites": "[]", "desired_collaboration": "", "comments": "", "affiliations": [ { "id": 289, "ror": "https://ror.org/024mw5h28", "name": "University of Chicago", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 289, "ror": "https://ror.org/024mw5h28", "name": "University of Chicago", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true }, "abstract": "The Institute for Translational Medicine (ITM) at the University of Chicago (UChicago) proposes to purchase and install a large and flex indirect calorimeter (IC) to support leading research programs in metabolism, diabetes, obesity, disorders of thyroid function, the microbiome, inflammatory bowel disease, weight reduction, frailty, circadian biology, and kidney disorders, among others. IC is the gold standard for measuring energy expenditure (EE) providing precise and accurate measures under regulated environmental conditions, ranging from maximal physical activity to sleep (SMR). For over 15 years UChicago investigators have measured EE using metabolic carts and doubly-labelled water, which only measures resting EE or RMR, for a limited duration (maximum 4 hours), requiring an over-the-head hood placement, limiting free mobility and with less precision than IC. Despite these limitations, UChicago NIH-funded investigators have incorporated measures of EE since 2004 resulting in highly impactful scientific findings. The IC proposed in this application is the only equipment available for long term (24hrs or more) EE measurements, that can determine circadian EE (ie RMR vs. SMR) with strictly controlled environmental conditions while aspects of daily life are evaluated including eating or thermal effects of food (TEF), sleeping (SMR) and physical activity. With the establishment of the Microbiome Center in 2015 and the Duchossois Family Institute in 2017 at UChicago, world-leading programs in the microbiome in health and disease are now being established. There is strong evidence for the impact of the microbiome on EE in a variety of complex medical disorders such as obesity, anorexia, metabolic syndrome, diabetes, circadian biology, chronic kidney disease, post COVID 19 syndromes, congestive heart failure and inflammatory bowel disease. However, EE changes associated with these disorders are nuanced and limitations in precision and accuracy require better instrumentation. Use of the IC proposed in this application will help to optimize patient long-term health in a variety of medical settings. By having capacity for IC measurement of EE while collecting biofluids simultaneously in a controlled environment, the contributory roles of the microbiome, metabolism and circadian biology can be characterized. Through the ITM, a multi-institution CTSA program partnered with Rush University and affiliated with Loyola University, Northshore Hospital, Advocate Center and the Illinois Institute for Technology, city-wide utilization of the IC will be facilitated and supported. Investigators from other Chicago- based institutions including Northwestern University and University of Illinois, and regional or great lakes such as University of Wisconsin and the Nutrition Obesity Research Center (NORC) investigators from University of Michigan, will perform scientific investigations. Seminars with experienced investigators in EE from other sites will advance and disseminate scientific findings from this center and advance multiple fields forward.", "keywords": [ "Advocate", "Anorexia", "Body Weight decreased", "Chicago", "Chronic Kidney Failure", "Cities", "Complex", "Congestive Heart Failure", "Controlled Environment", "Diabetes Mellitus", "Disease", "Eating", "Energy Metabolism", "Equipment", "Family", "Food", "Funding", "Gold", "Head", "Health", "Hospitals", "Hour", "Illinois", "Inflammatory Bowel Diseases", "Institutes", "Institution", "Investigation", "Kidney Diseases", "Life", "Long COVID", "Measurement", "Measures", "Medical", "Metabolic", "Metabolic syndrome", "Metabolism", "Michigan", "Obesity", "Patients", "Physical activity", "Research", "Research Personnel", "Rest", "Role", "Site", "Sleep", "Technology", "Thyroid Diseases", "Thyroid Function Tests", "United States National Institutes of Health", "Universities", "Wisconsin", "base", "circadian", "circadian biology", "doubly-labeled water", "experience", "frailty", "instrumentation", "microbiome", "nutrition", "programs", "standard measure", "translational medicine" ], "approved": true } }, { "type": "Grant", "id": "10414", "attributes": { "award_id": "1S10OD030381-01A1", "title": "7T Cryogen-Free Preclinical MRI for small animals to study infectious diseases in BSL-3 containment", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 25507, "first_name": "Xiang-Ning", "last_name": "Li", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-20", "end_date": "2023-09-19", "award_amount": 1695141, "principal_investigator": { "id": 21010, "first_name": "Sanjay", "last_name": "Jain", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 344, "ror": "https://ror.org/00za53h95", "name": "Johns Hopkins University", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "Infectious diseases are a major threat to humanity, and new tools are needed to study disease pathogenesis and aid the development of novel diagnostics, biomarkers and therapeutics. The alarming rise of highly virulent and multi-drug resistant (MDR) pathogens, their rapid spread, global pandemics such as COVID-19 and continued life-threatening nosocomial infections in hospitals, remain as major challenges to human health. Tomographic molecular imaging enables rapid, noninvasive visualization, localization and monitoring of molecular processes deep within the body and offers several advantages over traditional tools used for the study of infectious diseases. We are requesting a 7T Cryogen-Free preclinical Magnetic Resonance Imaging (MRI) system manufactured by MR Solutions (model 7024) to study infectious diseases in biosafety level-3 (BSL-3) containment at a centralized core facility. Since 2009, the Johns Hopkins Center for Infection and Inflammation Imaging Research (Ci3R) has developed and supported preclinical molecular imaging (PET, SPECT, CT) for infections and inflammatory disorders and established an entirely new user base comprising several NIH- funded infectious diseases investigators within the Johns Hopkins University. While many investigators study Mycobacterium tuberculosis and more recently SARS-CoV-2 – both of which are designated as BSL-3 pathogens with special biosafety needs – Ci3R also supports other researchers that study MDR bacteria (e.g. MRSA) and viral agents such as Zika. Several new approaches for infection imaging have been developed at Ci3R and translated to the clinic. MRI has many advantages over radiopharmaceutical imaging, including high-spatial resolution and contrast. 1H and 19F MR spectroscopic imaging (19F MRSI) and chemical exchange saturation transfer (CEST) contrast would support complementary approaches for molecular imaging of infectious diseases. Therefore, the addition of a high-field preclinical MRI will greatly boost the research efforts related to infectious diseases imaging, while also leveraging the strong MRI expertise within Johns Hopkins University led by NIH-funded investigators. Imaging technologies for infectious diseases are an emerging field of research and overcome several fundamental limitations of current tools in infectious diseases. Therefore, these technologies can have a broad impact on both basic research and patient care. Beyond diagnosis and monitoring infections, these technologies will also provide a uniform cross-species platform for animal studies, allow unique insights into understanding disease pathogenesis and expedite bench-to-bedside translation of new therapeutics. Finally, since MRI is readily available for humans, including high-field 7T systems, validated techniques may become valuable tools for clinical applications in infectious diseases and for enabling precision medicine.", "keywords": [ "2019-nCoV", "Animals", "Basic Science", "COVID-19", "Chemicals", "Clinic", "Communicable Diseases", "Containment", "Core Facility", "Development", "Diagnosis", "Disease", "Emerging Communicable Diseases", "Funding", "Health", "Hospitals", "Human", "Image", "Imaging technology", "Infection", "Inflammation", "Inflammatory", "Life", "Magnetic Resonance Imaging", "Modeling", "Molecular", "Monitor", "Multiple Bacterial Drug Resistance", "Mycobacterium tuberculosis", "Nosocomial Infections", "Pathogenesis", "Patient Care", "Positron-Emission Tomography", "Process", "Radiopharmaceuticals", "Research", "Research Personnel", "Resolution", "System", "Techniques", "Technology", "Therapeutic", "Translating", "United States National Institutes of Health", "Universities", "Viral", "Virulent", "Visualization", "ZIKA", "base", "bench-to-bedside translation", "clinical application", "diagnostic biomarker", "imaging system", "insight", "methicillin resistant Staphylococcus aureus", "molecular imaging", "multi-drug resistant pathogen", "novel diagnostics", "novel strategies", "novel therapeutics", "pandemic disease", "pathogen", "pre-clinical", "precision medicine", "single photon emission computed tomography", "spectroscopic imaging", "tomography", "tool" ], "approved": true } }, { "type": "Grant", "id": "10415", "attributes": { "award_id": "1S06GM146122-01", "title": "Environmental Influences Driving Autoimmunity and Autoimmune Disease in Tribal Members", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of General Medical Sciences (NIGMS)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2022-09-20", "end_date": "2026-07-31", "award_amount": 372113, "principal_investigator": { "id": 10936, "first_name": "JUDITH A", "last_name": "JAMES", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1109, "ror": "", "name": "UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR", "address": "", "city": "", "state": "OK", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1813, "ror": "https://ror.org/00p23dy23", "name": "Cherokee Nation", "address": "", "city": "", "state": "OK", "zip": "", "country": "United States", "approved": true }, "abstract": "OMRF Project Summary Rheumatic diseases, such as systemic lupus erythematosus (SLE, lupus), rheumatoid arthritis (RA), scleroderma and osteoarthritis, cause significant morbidity and early mortality in Native American populations. Through ongoing collaborative work between the Cherokee Nation and the Oklahoma Medical Research Foundation, we have found that classic autoantibody associations in rheumatic disease patients of other races are not diagnostic in NA populations, identified novel autoantibodies in tribal rheumatic disease patents and found that tribal patients and controls have unique cytokine signatures; all of which make rheumatic disease care in tribal members more challenging to diagnose in primary care clinics. Surprisingly, we found that Native American individuals without evidence of autoimmune rheumatic disease had the highest rate of autoantibody production (10.5%) of all races, primarily with lupus, systemic sclerosis or rheumatoid arthritis associated antibodies. Autoantibody production is associated with lower levels of 25(OH)D in these individuals. Anti- cardiolipin autoantibodies are also more frequent in NA rheumatic disease patients and controls. Some of the highest rates of infection, poor outcomes and deaths from COVID have occurred in tribal communities, and COVID induces autoantibodies in many otherwise healthy individuals, including anti- cardiolipin responses that associate with thrombosis and anti-cytokine responses that associate with poor disease outcomes. In studies from our group and others, many COVID patients with autoimmunity or autoimmune disease are having prolonged symptoms, which are reminiscent of rheumatic diseases, such as fatigue, arthralgias, myalgias, malaise, rashes, lung and heart involvement. Select environmental factors have strong associations with systemic autoimmune rheumatic diseases. This project will define the impact of environmental influences, such as viral infections (SARS-CoV-2, Epstein-Barr virus, Cytomegalovirus), viral reactivation (Epstein-Barr virus), vitamin D deficiency and smoking exposure, on the development of autoantibodies and autoimmune disease in tribal members. Using single cell mass cytometry time of flight (CyTOF) and single cell genomic sequencing partnered with antibody binding (CITE-seq), shared immune pathways contributing to loss of self-tolerance, autoantibody production and autoimmune rheumatic disease will be determined. Finally, through implementation of a telerheumatology, telementoring program focused on practice-centric, case-based learning, academic detailing, and patient enrollment to clinical research protocols rheumatology capacity within the Cherokee Nation Health System will be developed for current and future patients. The overall goals of this project are to identify and confirm environmental influences associated with autoantibody production, immune dysregulation and autoimmune rheumatic disease, as well as build lasting tribal-based infrastructure to provide ongoing rheumatic disease evaluation and treatment that aid earlier detection, decreased morbidity and improved outcomes in tribal patients.", "keywords": [ "2019-nCoV", "Academic Detailing", "Algorithms", "Antibodies", "Arthralgia", "Autoantibodies", "Autoimmune", "Autoimmune Diseases", "Autoimmunity", "Automobile Driving", "Binding", "COVID-19", "COVID-19 impact", "COVID-19 patient", "Caring", "Case Based Learning", "Cells", "Cellular Indexing of Transcriptomes and Epitopes by Sequencing", "Cessation of life", "Cherokee Indian", "Cherokee Nation Oklahoma", "Cities", "Clinic", "Clinical Research", "Clinical Research Protocols", "Cotinine", "Cytomegalovirus", "Cytometry", "Data", "Degenerative polyarthritis", "Development", "Diagnosis", "Disease Outcome", "Dissemination and Implementation", "Early Diagnosis", "Early Intervention", "Early treatment", "Enrollment", "Environmental Exposure", "Environmental Impact", "Environmental Risk Factor", "Epstein-Barr virus early antigen", "Evaluation", "Exanthema", "Fatigue", "Foundations", "Future", "Genomics", "Goals", "Grant", "Health", "Health system", "Heart", "Human Herpesvirus 4", "Immune", "Immune System Diseases", "Immunophenotyping", "Individual", "Infection", "Infrastructure", "Legal patent", "Long COVID", "Lung", "Lupus", "Malaise", "Measures", "Medical Research", "Mentors", "Methods", "Morbidity - disease rate", "Myalgia", "Native American Research Center for Health", "Native Americans", "Oklahoma", "Outcome", "Pathway interactions", "Patients", "Population", "Prevention", "Primary Health Care", "Production", "Provider", "Race", "Rheumatism", "Rheumatoid Arthritis", "Rheumatology", "Rivers", "SARS-CoV-2 infection", "Scleroderma", "Self Tolerance", "Symptoms", "Systemic Lupus Erythematosus", "Systemic Scleroderma", "Testing", "Thrombosis", "Time", "Vaccines", "Viral", "Virus Diseases", "Vitamin D Deficiency", "Work", "autoimmune rheumatologic disease", "base", "care providers", "coronavirus disease", "cytokine", "immunoregulation", "improved outcome", "infection rate", "mortality", "multiple omics", "novel", "participant enrollment", "programs", "proteogenomics", "response", "rheumatologist", "single-cell RNA sequencing", "smoking exposure", "systemic autoimmune disease", "tribal community", "tribal member" ], "approved": true } }, { "type": "Grant", "id": "10416", "attributes": { "award_id": "1R21HD105183-01A1", "title": "Prejudices and Discrimination Toward Asians and Hispanics During and After COVID-19", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)" ], "program_reference_codes": [], "program_officials": [ { "id": 9683, "first_name": "REGINA M", "last_name": "BURES", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-15", "end_date": "2024-08-31", "award_amount": 244943, "principal_investigator": { "id": 26411, "first_name": "NEERAJ", "last_name": "KAUSHAL", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 922, "ror": "", "name": "COLUMBIA UNIV NEW YORK MORNINGSIDE", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "Prejudices and Discrimination Toward Asians and Hispanics During and After COVID-19 Abstract The COVID-19 pandemic has led to growing concerns of racism and xenophobia. Results from our nationally representative online survey experiment of 5,000 Americans, conducted in August 2020, show that, when reminded of the adversities of COVID-19, respondents reported heightened prejudice and discrimination toward ethnic minorities, particularly Asians and Hispanics. The ensuing questions are: will such racism and xenophobia abate when the society and economy return to normal, what mechanisms will moderate changes in racist attitudes, and what are the implications of these attitudinal shifts for the well-being of minorities? We propose to investigate these questions with longitudinal data collection and analyses. Specifically, we will collect a second wave of nationally representative online survey experiment to study changes in prejudice and discrimination against minorities as the nation recovers from COVID-19. Further, we will study the economic and psychological well-being of minority groups before, during, and after COVID-19 using our survey data, which includes a new module of retrospective measures for an oversample of minority groups. At the theoretical level, our project adds to theories of racism and inter-group relations by examining (i) insecurities and threats triggered by the pandemic and their impacts on attitudes and behavioral orientations toward minorities; (ii) the abatement of these prejudices and discrimination as the society recovers; (iii) the factors that moderate the abatement process; and (iv) the economic and psychological effects of COVID-19 on minority groups using retrospective history data starting a year prior to the pandemic. At the empirical level, this project builds on a nationally representative longitudinal online survey experiment conducted during and after the pandemic, which is a novel contribution. The nationally representative sample allows for generalization of the findings. The longitudinal design strengthens causal inference and facilitates assessment of changes in attitudes and behavioral intent over time, and factors shaping such change. Findings from our proposed research will inform policymakers and the society at large about the extent and urgency of the issue that can facilitate the development of initiatives to reduce racism and xenophobia toward minorities. Our data on histories of minority experiences during and after the pandemic will provide important information for policy and research on the vulnerabilities and resilience of minorities during and post-societal crises. In particular, the moderation analyses will be beneficial for public policies as they help identify factors that can be leveraged to reduce racism and xenophobia in workplace and social settings.", "keywords": [ "Abate", "Address", "Affect", "American", "Asian population", "Attitude", "Behavior", "Behavioral", "COVID-19", "COVID-19 impact", "COVID-19 outbreak", "COVID-19 pandemic", "Cessation of life", "China", "County", "Data", "Data Analyses", "Data Collection", "Development", "Dimensions", "Discrimination", "Economics", "Employment", "Event", "Family member", "Health", "Hispanic Populations", "Hostility", "Immigrant", "Individual", "Interview", "Job loss", "Latinx population", "Life", "Longitudinal Surveys", "Measures", "Methods", "Minority", "Minority Groups", "National Security", "Nature", "Perception", "Personal Satisfaction", "Policy Research", "Politics", "Prejudice", "Prevalence", "Process", "Public Policy", "Recording of previous events", "Recovery", "Reporting", "Research", "Respondent", "Sampling", "Shapes", "Shock", "Societies", "Surveys", "Testing", "Time Factors", "Unemployment", "Wages", "Well in self", "Workplace", "base", "combat", "coronavirus disease", "design", "ethnic diversity", "ethnic minority", "ethnoracial minority", "experience", "experimental study", "falls", "health economics", "longitudinal design", "member", "news", "novel", "novel strategies", "pandemic disease", "perceived discrimination", "post-COVID-19", "psychologic", "racism", "resilience", "social", "theories" ], "approved": true } }, { "type": "Grant", "id": "10417", "attributes": { "award_id": "1R01HD105502-01A1", "title": "Optimizing a Personalized Health Approach for Virtually Treating High-Risk Caregivers During COVID-19 and Beyond", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)" ], "program_reference_codes": [], "program_officials": [ { "id": 6227, "first_name": "Tracy", "last_name": "King", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-23", "end_date": "2025-06-30", "award_amount": 1028367, "principal_investigator": { "id": 26412, "first_name": "Bridgette Lynne", "last_name": "Kelleher", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1139, "ror": "", "name": "PURDUE UNIVERSITY", "address": "", "city": "", "state": "IN", "zip": "", "country": "United States", "approved": true }, "abstract": "With the spread of COVID-19, public health precautions have required physical distancing and a variety of shelter-in-place orders, causing rapid and substantial shifts in all aspects of family and community life. Data from COVID-19, supported by evidence from past national emergencies, suggest caregivers are at clear risk for secondary health effects because of the current pandemic. COVID-19 has been described as a “perfect vector for a mental health epidemic” due to the accumulated effects of pandemic-related fear, social isolation, post-traumatic stress, and mental health treatment barriers. These changes to daily life have been especially challenging for families of children with neurogenetic conditions (NGC), who experience high levels of baseline stress, are particularly vulnerable to reductions in targeted therapeutic services, and rely on medical and educational services that have been disrupted by COVID-19 related closures. Specifically, caregivers themselves are vulnerable to stress-related mental and physical health challenges because of the pandemic; they rarely receive treatment for their own mental health needs, and any treatments they do receive are typically disconnected from their child's care plan and are delivered by practitioners with little-to-no expertise in the needs of NGC families. These health care gaps are amplified among Black and other minority families. The proposed study will address the needs of caregivers of children with NGC by examining the feasibility, efficacy, and impact of a novel network for delivering personalized triage and digital treatment. Specifically, we propose to scale up and integrate a series of brief, evidence based digital health interventions to support caregiver mental health, parenting self-efficacy, and stress. Supervised graduate student trainees will implement rigorous, cost-effective, evidence-based interventions via telehealth. A key innovation of this work is that we will develop a personalized health routing algorithm that matches participants with relevant treatments using both clinical inputs and ecological momentary assessment (EMA) data, brief questionnaires “pinged” to caregiver phones via a smartphone app. A second innovation is that we will test the efficacy of peer-to-peer coaching in enhancing treatment uptake and outcomes. Coaching will be delivered by fellow NGC caregivers using an evidence-based motivational interviewing protocol. By the end of the award period, we will have generated a novel, scalable, and cost-effective solution for rapidly meeting acute needs for NGC caregivers through personalized, digital delivery of evidence-based treatments. This model can be rapidly scaled for other high-risk populations during COVID-19 (e.g. first responders, teachers, frontline workers) and future public health crises. Given substantial unmet needs existed among NGC families even prior to COVID- 19, this protocol has potential to fundamentally shift the status-quo for how treatment is selected and accessed in NGC caregivers and other underserved groups, including beyond the COVID-19 pandemic.", "keywords": [ "Acute", "Address", "Algorithms", "Award", "Behavior", "Behavior Therapy", "Black race", "COVID-19", "COVID-19 impact", "COVID-19 pandemic", "COVID-19 pandemic effects", "Caregiver support", "Caregivers", "Caring", "Cellular Phone", "Child", "Child Care", "Child Rearing", "Clinic", "Clinical", "Communication", "Communities", "Complex", "Data", "Diagnostic", "Distress", "Ecological momentary assessment", "Effectiveness", "Emergency Situation", "Epidemic", "Evidence based intervention", "Evidence based treatment", "Face", "Family", "Family Caregiver", "Financial Hardship", "Fright", "Frontline worker", "Future", "Geography", "Health", "Health Services Accessibility", "Healthcare", "Infrastructure", "Intervention", "Life", "Longitudinal Studies", "Medical", "Mental Health", "Methods", "Minority", "Modeling", "Monitor", "Outcome", "Participant", "Patients", "Protocols documentation", "Provider", "Public Health", "Questionnaires", "Randomized", "Risk", "Route", "Self Efficacy", "Series", "Services", "Shelter facility", "Social isolation", "Stress", "Supervision", "Symptoms", "Syndrome", "Training", "Trauma", "Triage", "Underserved Population", "Vulnerable Populations", "Work", "base", "caregiving", "clinically significant", "compare effectiveness", "cost effective", "cost efficient", "design", "digital", "digital delivery", "digital health", "digital healthcare", "digital intervention", "digital mental health", "digital treatment", "efficacy testing", "evidence base", "experience", "feasibility testing", "first responder", "functional disability", "graduate student", "health disparity", "high risk", "high risk population", "innovation", "meetings", "motivational enhancement therapy", "neurogenetics", "novel", "pandemic disease", "peer", "peer coaching", "personalized medicine", "physical conditioning", "post-traumatic stress", "prevent", "response", "scale up", "service intervention", "smartphone Application", "targeted treatment", "teacher", "telehealth", "therapy design", "tool", "treatment as usual", "uptake", "vector", "virtual" ], "approved": true } }, { "type": "Grant", "id": "10418", "attributes": { "award_id": "1S10OD030417-01A1", "title": "Automated Multiscale Super-resolution Confocal Microscope", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 11602, "first_name": "GUANGHU", "last_name": "Wang", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-15", "end_date": "2023-09-14", "award_amount": 514425, "principal_investigator": { "id": 26413, "first_name": "William", "last_name": "Kiosses", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 777, "ror": "", "name": "LA JOLLA INSTITUTE FOR IMMUNOLOGY", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "The La Jolla Institute for Immunology (LJI) is a premier immunology research institute in the US whose 20 principal investigators are supported by ~$39 million in NIH grants and contracts. At LJI, we study the behavior of immune cells in diseases prominent in the US and around the world, including viral biology, type 1 diabetes, atherosclerosis, cancer, and inflammation. Nearly all of our scientists use imaging to visualize cellular interactions, signaling, and function with results published in Nature, Science, and other prominent journals. However, as our research aims evolve, and to progress further in the research projects listed in this application, we need a reliable and versatile super-resolution confocal microscope with multiscale imaging capability. The LJI Microscopy and Histology Core Facility is a dynamic, scientifically driven, multi-user resource with a remarkable potential for growth. The instrumentation in the LJI Microscopy Core Facility includes an aging Zeiss LSM 780 that is used by many NIH funded projects, with aims ranging from the investigation of matrix protein assembly in SARS-CoV-2, novel cell types in atherosclerosis, molecular pathways leading to Type 1 diabetes, and many others. This system is nearing the end of its useful lifetime and a replacement microscope is needed. Here, we seek support for purchasing an automated, state-of-the-art, super-resolution microscope that allows for multiscale, high-throughput investigation of mouse and human tissues. Dynamic biological processes can be probed thanks to innovative software, highly sensitive detectors, and unparalleled acquisition speed. After comparing instruments on the market from all major companies, it is clear that the Zeiss LSM 980 with Airyscan 2 system is the best suited for the needs of LJI investigators and collaborators, and if funded, it will undoubtedly have a significant impact on NIH-supported scientific progress.", "keywords": [ "2019-nCoV", "Aging", "Atherosclerosis", "Biological Process", "Biology", "Cells", "Computer software", "Core Facility", "Disease", "Funding", "Growth", "Histology", "Image", "Immune", "Immunology", "Inflammation", "Institutes", "Insulin-Dependent Diabetes Mellitus", "Investigation", "Journals", "Malignant Neoplasms", "Microscope", "Microscopy", "Molecular", "Mus", "NIH Grants and Contracts", "Nature", "Pathway interactions", "Principal Investigator", "Proteins", "Publishing", "Research", "Research Institute", "Research Personnel", "Research Project Grants", "Resolution", "Resources", "Science", "Scientist", "Signal Transduction", "Speed", "System", "United States National Institutes of Health", "Viral", "behavioral study", "cell type", "detector", "human tissue", "imaging capabilities", "innovation", "instrument", "instrumentation", "novel" ], "approved": true } }, { "type": "Grant", "id": "10419", "attributes": { "award_id": "1P01AI165066-01", "title": "Development of broad nanovaccines targeting diverse coronavirus receptor-binding sites", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2022-09-22", "end_date": "2025-08-31", "award_amount": 1244471, "principal_investigator": { "id": 11662, "first_name": "Daniel", "last_name": "Kulp", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1141, "ror": "", "name": "WISTAR INSTITUTE", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1141, "ror": "", "name": "WISTAR INSTITUTE", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "The first project of our pan-CoV proposal is titled ‘Development of broad nanovaccines targeting diverse coronavirus receptor-binding sites’. Our team’s expertise will culminate in structurally guided coronavirus nanoparticle vaccines to broaden CoV vaccine protection. This proposal utilizes our novel platform to develop potent, RBS-focused nanoparticle vaccines to induce broad protection across CoV lineages, escape mutations and potential pandemic CoVs that are of concern. The project aims are: (1) Create a library of mutants that escape coronavirus immunity (2) Develop RBS-focused nanoparticle vaccines to induce broadly neutralizing antibodies to conserved sites using nucleic acid delivery and (3) Develop vaccine regimens to induce broad immunity and protection across diverse CoVs.", "keywords": [ "2019-nCoV", "Address", "Adjuvant", "Antibodies", "Antibody Repertoire", "Antibody Response", "Antigens", "Automobile Driving", "B-Lymphocytes", "Binding", "Binding Sites", "CD8-Positive T-Lymphocytes", "COVID-19 therapeutics", "COVID-19 vaccination", "COVID-19 vaccine", "Coronavirus", "Coronavirus Infections", "Cryoelectron Microscopy", "DNA", "DNA Vaccines", "Development", "Devices", "Disease Outbreaks", "Dose", "Electroporation", "Epitopes", "Escape Mutant", "FDA Emergency Use Authorization", "Frequencies", "Generations", "Genetic", "Genetic Recombination", "Human", "Immune Sera", "Immune response", "Immunity", "Immunization", "Immunization Programs", "Investigation", "Libraries", "Middle East Respiratory Syndrome Coronavirus", "Modeling", "Molecular", "Mutagenesis", "Mutate", "Mutation", "Nucleic Acids", "Phenotype", "Preclinical Testing", "Publishing", "Regimen", "Research Project Grants", "SARS coronavirus", "SARS-CoV-2 spike protein", "Site", "Technology", "Transgenic Animals", "Vaccine Clinical Trial", "Vaccines", "Variant", "Virus", "Widespread Disease", "animal data", "base", "betacoronavirus", "clinical translation", "combat", "coronavirus receptor", "coronavirus vaccine", "cross reactivity", "design", "experimental study", "human coronavirus", "immunogenicity", "interest", "lead candidate", "mutant", "nanoparticle", "nanoparticle delivery", "nanovaccine", "neutralizing antibody", "novel", "novel coronavirus", "nucleic acid delivery", "pandemic disease", "pathogenic virus", "plasmid DNA", "pre-clinical", "programs", "receptor", "receptor binding", "synergism", "universal coronavirus vaccine", "vaccine candidate", "vaccine development", "vaccinology" ], "approved": true } } ], "meta": { "pagination": { "page": 1385, "pages": 1419, "count": 14184 } } }